Australia Stock Exchange release from CLARITY PHARMACE : First patient treated in cohort 2 neuroblastoma trial
24/02/2022 22:28
Australia Stock Exchange release from CLARITY PHARMACE CU6.AX : First patient treated in cohort 2 neuroblastoma trial
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial